Edgewise Therapeutics , Inc., a biotechnology company specializing in pharmaceutical preparations, announced the promotion of ...

BOULDER, Colo. - Edgewise Therapeutics Inc. (NASDAQ:EWTX), a biopharmaceutical company focused on muscle disease treatment ...

Edgewise Therapeutics (EWTX) stock traded flat as Stifel launched its coverage with a Hold recommendation, indicating a ...

Edgewise Therapeutics Inc (EWTX) stock saw a modest uptick, ending the day at $28.3 which represents a slight increase of $1.30 or 4.81% from the prior close of $27. The stock opened at $26.84 and ...

Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Free Report) was the target of a significant growth in short interest during ...

Paul Matteis, an analyst from Stifel Nicolaus, has initiated a new Hold rating on Edgewise Therapeutics (EWTX).Invest with Confidence: Follow ...

In this article, we are going to take a look at where Edgewise Therapeutics, Inc. (NASDAQ:EWTX) stands against Andreas Halvorsen’s other long-term stock picks. Andreas Halvorsen is a prominent ...

Edgewise Therapeutics Inc. (Nasdaq: EWTX) has promoted Behrad Derakhshan, formerly the Boulder-based muscle disease biopharmaceutical company’s chief business officer, to chief operating officer, and ...

- Behrad Derakhshan, Ph.D. promoted to Chief Operating Officer (COO) - Robert Blaustein, M.D., Ph.D., Chief Development Officer, Edgewise Therapeutics (Photo ...

Presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 1:30 p.m. PT (4:30 p.m. ET) - Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Piper Sandler has maintained a confident stance on Edgewise Therapeutics (NASDAQ: EWTX), reiterating an Overweight rating with a $48.00 price target. The firm's optimism is tied ...